Does plerixafor ( a CXCR4 antagonist ) following myeloablative allogeneic hematopoietic stem cell transplantation enhance hematopoietic recovery?
Our study demonstrated that plerixafor can be given safely following myeloablative HSCT. It provides proof of principle that blocking CXCR4 after HSCT enhances hematopoietic recovery. Larger, confirmatory studies in other settings are warranted.
Subtype F and subtype D strains, uncommon in West Africa, are a substantial part of HIV-1 epidemiology in Guinea.